| Q35582270 | (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. |
| Q36024044 | Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells |
| Q33841673 | Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors |
| Q42061450 | Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors |
| Q38187815 | Apoptosis inducers in chronic lymphocytic leukemia |
| Q38066407 | Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer |
| Q42773124 | Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells |
| Q26823996 | Bcl-2 antagonists: a proof of concept for CLL therapy |
| Q55027218 | Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. |
| Q36862781 | Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications |
| Q36689108 | Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q37625487 | CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. |
| Q38110472 | Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment |
| Q28082086 | Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment |
| Q36746585 | Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells |
| Q36629141 | Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737 |
| Q37997623 | Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia |
| Q39798268 | Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance |
| Q36224948 | Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms |
| Q34455521 | Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells |
| Q35409569 | Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia |
| Q34285051 | Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL |
| Q51173647 | HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. |
| Q34568840 | Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia |
| Q38263806 | Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia |
| Q34231324 | Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia |
| Q37778876 | Inflammation and survival pathways: chronic lymphocytic leukemia as a model system |
| Q34122323 | Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells |
| Q37460333 | Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy |
| Q42446777 | Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells |
| Q37827279 | Leukemia stem cells and microenvironment: biology and therapeutic targeting |
| Q33989964 | Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression |
| Q28539921 | Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide |
| Q37187536 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia |
| Q37504699 | Molecular and cellular mechanisms of CLL: novel therapeutic approaches. |
| Q35127368 | Molecular targeted approaches in mantle cell lymphoma |
| Q33757336 | Myogenic differentiation of VCP disease-induced pluripotent stem cells: A novel platform for drug discovery |
| Q39196767 | Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma |
| Q26821766 | New molecular targets in mantle cell lymphoma |
| Q39431412 | Novel agents in indolent lymphomas. |
| Q36612602 | Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia |
| Q37983083 | Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms |
| Q54612791 | Personalizing treatment for chronic lymphocytic leukemia. |
| Q39627618 | Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis |
| Q35643843 | Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. |
| Q34081881 | Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia |
| Q30361951 | Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. |
| Q35125652 | Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation |
| Q37457562 | Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic |
| Q39652589 | Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells. |
| Q37840932 | Refractory chronic lymphocytic leukemia--new therapeutic strategies |
| Q35022490 | Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia |
| Q42444933 | RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow |
| Q64948157 | Renieramycin T Induces Lung Cancer Cell Apoptosis by Targeting Mcl-1 Degradation: A New Insight in the Mechanism of Action. |
| Q33695176 | RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo |
| Q42183094 | Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q37362593 | STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia. |
| Q34742904 | Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway |
| Q36557448 | Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. |
| Q37799747 | Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. |
| Q30994095 | Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells |
| Q83770207 | Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia |
| Q35599741 | Targeted treatment for chronic lymphocytic leukemia |
| Q27024422 | Targeting the apoptosis pathway in hematologic malignancies |
| Q38193997 | Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q45916401 | The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. |
| Q38766548 | The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia |
| Q42222764 | The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells |
| Q38597740 | The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells |
| Q28075683 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia |
| Q42389003 | The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions |
| Q48121335 | The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. |
| Q39722770 | The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia |
| Q36300303 | Therapeutic advancement of chronic lymphocytic leukemia |
| Q39120136 | Therapeutic inhibition of BCL-2 and related family members |
| Q37964916 | Treatment of relapsed or refractory chronic lymphocytic leukemia |
| Q34401328 | Using functional genomics to overcome therapeutic resistance in hematological malignancies. |
| Q33780816 | Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed |
| Q37092954 | Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. |